fluoxetine has been researched along with Myasthenia Gravis in 2 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 9.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| "To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration." | 5.09 | Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cetin, H | 1 |
| Webster, R | 1 |
| Liu, WW | 1 |
| Nagaishi, A | 1 |
| Koneczny, I | 1 |
| Zimprich, F | 1 |
| Maxwell, S | 1 |
| Cossins, J | 1 |
| Beeson, D | 1 |
| Vincent, A | 1 |
| Achiron, A | 1 |
| Barak, Y | 1 |
| Noy, S | 1 |
| Pinhas-Hamiel, O | 1 |
1 trial available for fluoxetine and Myasthenia Gravis
| Article | Year |
|---|---|
Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Female; | 1999 |
1 other study available for fluoxetine and Myasthenia Gravis
| Article | Year |
|---|---|
Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.
Topics: Adolescent; Adult; Aged; Autoantibodies; Bungarotoxins; Cell Line; Electrophysiological Phenomena; F | 2020 |